Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer

Journal of Clinical Oncology

Volumn 35, Issue 17, 2017, Pages 1884-1890

  Catton, Charles N ^a   Lukka, Himu ^b   Gu, Chu Shu ^b   Martin, Jarad M ^h   Supiot, Stéphane ^k   Chung, Peter W M ^a   Bauman, Glenn S ^c   Bahary, Jean Paul ^d   Ahmed, Shahida ^e   Cheung, Patrick ^a   Tai, Keen Hun ⁱ   Wu, Jackson S ^f   Parliament, Matthew B ^g   Tsakiridis, Theodoros ^b   Corbett, Tom B ^b   Tang, Colin ^j   Dayes, Ian S ^b   Warde, Padraig ^a   Craig, Tim K ^a   Julian, Jim A ^b   Levine, Mark N ^b   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^k UNIVERSITÉ DE NANTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL CLINICAL FAILURE; BIOCHEMICAL RECURRENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 85021768552     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.7397     Document Type: Article

References (31)

1. National Comprehensive Cancer Network: Prostate cancer, 2016. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
2. Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095-1101, 1999
3. Fowler J, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021-1031, 2001
4. Lukka H, Hayter C, Julian JA, et al: Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23:6132-6138, 2005
5. Brenner DJ, Martinez AA, Edmundson GK, et al: Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6-13, 2002
6. Miralbell R, Roberts SA, Zubizarreta E, et al: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: a/b = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 82:e17-e24, 2012
7. Wortel RC, Incrocci L, Pos FJ, et al: Late side effects after image guided intensity modulated radiation therapy compared to 3D-conformal radiation therapy for prostate cancer: Results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys 95: 680-689, 2016
8. Dearnaley DP, Khoo VS, Norman AR, et al: Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 353:267-272, 1999
9. Dearnaley DP, Sydes MR, Graham JD, et al: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475-487, 2007
10. Kuban DA, Tucker SL, Dong L, et al: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70: 67-74, 2008
11. Zietman AL, Bae K, Slater JD, et al: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage ad-enocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 28: 1106-1111, 2010
12. Lee WR, Dignam JJ, Amin MB, et al: Randomised phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34:2325-2332, 2016
13. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA 277:1445-1451, 1997
14. Martin J, Frantzis J, Chung P, et al: Prostate radiotherapy clinical trial quality assurance: How real should real time review be? (A TROG-OCOG Intergroup Project). Radiother Oncol 107:333-338, 2013
15. Cox J, Grignon D, Kaplan R, et al: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
16. Roach M III, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65: 965-974, 2006
17. Wei JT, Dunn RL, Litwin MS, et al: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899-905, 2000
18. Ware J Jr, Kosinski M, Keller SD: A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 34:220-233, 1996
19. Aluwini S, Pos F, Schimmel E, et al: Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17: 464-474, 2016
20. Arcangeli S, Strigari L, Gomellini S, et al: Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84:1172-1178, 2012
21. Dearnaley D, Syndikus I, Mossop H, et al: Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, noninferiority, phase 3 CHHiP trial. Lancet Oncol 17: 1047-1060, 2016
22. Pollack A, Walker G, Horwitz EM, et al: Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31: 3860-3868, 2013
23. Hanks GE, Hanlon AL, Pinover WH, et al: Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46:823-832, 2000
24. Pollack A, Zagars GK, Starkschall G, et al: Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105, 2002
25. Zelefsky MJ, Fuks Z, Hunt M, et al: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876-881, 2001
26. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
27. Dearnaley DP, Jovic G, Syndikus I, et al: Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464-473, 2014
28. Syndikus I, Morgan RC, Sydes MR, et al: Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: Results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 77: 773-783, 2010
29. Sanguineti G, Arcidiacono F, Landoni V, et al: Macroscopic hematuria after conventional or hypofractionated radiation therapy: Results from a prospective phase 3 study. Int J Radiat Oncol Biol Phys 96:304-312, 2016
30. Lieng H, Pintilie M, Bayley A, et al: Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiother Oncol 122:93-96, 2017
31. Incrocci L, Wortel RC, Alemayehu WG, et al: Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17:1061-1069, 2016